Coinfection with hepatitis C virus and human immunodeficiency virus: Virological, immunological, and clinical outcomes

Journal of Virology

Volumn 83, Issue 15, 2009, Pages 7366-7374

  Rotman, Yaron ^a   Liang, T Jake ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTERFERON; NEVIRAPINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANEMIA; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DRUG POTENTIATION; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 67650863603     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00191-09     Document Type: Short Survey

References (136)

1. Albert, M. L., J. Decalf, and S. Pol. 2008. Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. J. Hepatol. 49:1069-1078.
2. Alter, M. J. 2006. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44:S6-9.
3. Antonucci, G., E. Girardi, A. Cozzi-Lepri, M. R. Capobianchi, A. De Luca, M. Puoti, E. Petrelli, G. Carnevale, G. Rizzardini, P. A. Grossi, P. Vigano, M. C. Moioli, F. Carletti, M. Solmone, G. Ippolito, and A. D. Monforte. 2005. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin. Infect. Dis. 40:e101-e109.
4. Antonucci, G., D. Goletti, S. Lanini, E. Girardi, and O. Loiacono. 2003. HIV/HCV co-infection: putting the pieces of the puzzle together. Cell Death Differ. 10:S25-S26.
5. Aranzabal, L., J. L. Casado, J. Moya, C. Quereda, S. Diz, A. Moreno, L. Moreno, A. Antela, M. J. Perez-Elias, F. Dronda, A. Marin, F. Hernandez-Ranz, A. Moreno, and S. Moreno. 2005. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis. 40:588-593.
6. Arnold, D. M., J. A. Julian, and I. R. Walker. 2006. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 108:460-464.
7. Babik, J. M., and M. Holodniy. 2003. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J. Virol. 77:1940-1950.
8. Balagopal, A., F. H. Philp, J. Astemborski, T. M. Block, A. Mehta, R. Long, G. D. Kirk, S. H. Mehta, A. L. Cox, D. L. Thomas, and S. C. Ray. 2008. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 135:226-233.
9. Balasubramanian, A., R. K. Ganju, and J. E. Groopman. 2006. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J. Infect. Dis. 194:670-681.
10. Bani-Sadr, F., F. Carrat, S. Pol, R. Hor, E. Rosenthal, C. Goujard, P. Morand, F. Lunel-Fabiani, D. Salmon-Ceron, L. Piroth, G. Pialoux, M. Bentata, P. Cacoub, and C. Perronne. 2005. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J. Acquir. Immune Defic. Syndr. 40:47-52.
11. Bani-Sadr, F., F. Carrat, E. Rosenthal, L. Piroth, P. Morand, F. Lunel-Fabiani, M. Bonarek, N. Colin de Verdiere, G. Pialoux, P. Cacoub, S. Pol, and C. Perronne. 2005. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin. Infect. Dis. 41:1806-1809.
12. Bani-Sadr, F., L. Denoeud, P. Morand, F. Lunel-Fabiani, S. Pol, P. Cacoub, C. Perronne, and F. Carrat. 2007. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J. Acquir. Immune Defic. Syndr. 45:123-125.
13. Bani-Sadr, F., I. Goderel, C. Penalba, E. Billaud, J. Doll, Y. Welker, P. Cacoub, S. Pol, C. Perronne, and F. Carrat. 2007. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. J. Viral Hepat. 14:639-644.
14. Barreiro, P., P. Labarga, L. Martin-Carbonero, A. Amor, A. Ruiz-Sancho, C. Castellares, J. Gonzalez-Lahoz, and V. Soriano. 2006. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir. Ther. 11:869-877.
15. Beld, M., M. Penning, V. Lukashov, M. McMorrow, M. Roos, N. Pakker, A. van den Hoek, and J. Goudsmit. 1998. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV sero-converters. Virology 244:504-512.
16. Benhamou, Y., M. Bochet, V. Di Martino, F. Charlotte, F. Azria, A. Coutellier, M. Vidaud, F. Bricaire, P. Opolon, C. Katlama, and T. Poynard. 1999. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30:1054-1058.
17. Berenguer, J., J. M. Bellon, P. Miralles, E. Alvarez, I. Castillo, J. Cosin, J. C. Lopez, M. Sanchez Conde, B. Padilla, and S. Resino. 2008. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis. 46:137-143.
18. Berenguer, M., V. Aguilera, M. Prieto, F. San Juan, J. M. Rayon, S. Benlloch, and J. Berenguer. 2006. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol. 44:717-722.
19. Bica, I., B. McGovern, R. Dhar, D. Stone, K. McGowan, R. Scheib, and D. R. Snydman. 2001. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32:492-497.
20. Blackard, J. T., Y. Yang, P. Bordoni, K. E. Sherman, and R. T. Chung. 2004. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J. Infect. Dis. 189:1472-1481.
21. Bollepalli, S., K. Mathieson, C. Bay, A. Hillier, J. Post, D. H. Van Thiel, and A. Nadir. 2007. Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients. Sex. Transm. Dis. 34:367-370.
22. Bonacini, M., S. Govindarajan, L. M. Blatt, P. Schmid, A. Conrad, and K. L. Lindsay. 1999. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J. Viral Hepat. 6:203-208.
23. Bower, W. A., D. H. Culver, D. Castor, Y. Wu, V. N. James, H. Zheng, S. Hammer, W. L. Kuhnert, I. T. Williams, B. P. Bell, D. Vlahov, and C. S. Dezzutti. 2006. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 42:293-297.
24. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, B. R. Blazar, B. Rodriguez, L. Teixeira-Johnson, A. Landay, J. N. Martin, F. M. Hecht, L. J. Picker, M. M. Lederman, S. G. Deeks, and D. C. Douek. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371.
25. Briat, A., E. Dulioust, J. Galimand, H. Fontaine, M. L. Chaix, H. Letur-Konirsch, S. Pol, P. Jouannet, C. Rouzioux, and M. Leruez-Ville. 2005. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 19:1827-1835.
26. Cacoub, P., L. Geffray, E. Rosenthal, C. Perronne, P. Veyssier, and G. Raguin. 2001. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin. Infect. Dis. 32:1207-1214.
27. Canchis, P. W., H. T. Yee, M. I. Fiel, D. T. Dieterich, R. C. Liu, L. Chiriboga, I. M. Jacobson, B. R. Edlin, and A. H. Talal. 2004. Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J. Acquir. Immune Defic. Syndr. 37:1125-1131.
28. Cao, Y. Z., D. Dieterich, P. A. Thomas, Y. X. Huang, M. Mirabile, and D. D. Ho. 1992. Identification and quantitation of HIV-1 in the liver of patients with AIDS. AIDS 6:65-70.
29. + T-cell responses to hepatitis C virus. J. Med. Virol. 79:503-510.
30. Carrat, F., F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, A. Benzekri, P. Morand, C. Goujard, G. Pialoux, L. Piroth, D. Salmon-Ceron, C. Degott, P. Cacoub, and C. Perronne. 2004. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292:2839-2848.
31. Chung, R. T., J. Andersen, P. Volberding, G. K. Robbins, T. Liu, K. E. Sherman, M. G. Peters, M. J. Koziel, A. K. Bhan, B. Alston, D. Colquhoun, T. Nevin, G. Harb, and C. van der Horst. 2004. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351:451-459.
32. Chung, R. T., S. R. Evans, Y. Yang, D. Theodore, H. Valdez, R. Clark, C. Shikuma, T. Nevin, and K. E. Sherman. 2002. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16:1915-1923.
33. Danta, M., D. Brown, S. Bhagani, O. G. Pybus, C. A. Sabin, M. Nelson, M. Fisher, A. M. Johnson, and G. M. Dusheiko. 2007. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21:983-991.
34. Danta, M., N. Semmo, P. Fabris, D. Brown, O. G. Pybus, C. A. Sabin, S. Bhagani, V. C. Emery, G. M. Dusheiko, and P. Klenerman. 2008. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J. Infect. Dis. 197:1558-1566.
35. De Carli, G., V. Puro, and G. Ippolito. 2003. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 31(Suppl. 2):22-27.
36. den Brinker, M., F. W. Wit, P. M. Wertheim-van Dillen, S. Jurriaans, J. Weel, R. van Leeuwen, N. G. Pakker, P. Reiss, S. A. Danner, G. J. Weverling, and J. M. Lange. 2000. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14:2895-2902.
37. Di Martino, V., P. Rufat, N. Boyer, P. Renard, F. Degos, M. Martinot-Peignoux, S. Matheron, V. Le Moing, F. Vachon, C. Degott, D. Valla, and P. Marcellin. 2001. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34:1193-1199.
38. Dolganiuc, A., S. Chang, K. Kodys, P. Mandrekar, G. Bakis, M. Cormier, and G. Szabo. 2006. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-α and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177:6758-6768.
39. Dolganiuc, A., O. Norkina, K. Kodys, D. Catalano, G. Bakis, C. Marshall, P. Mandrekar, and G. Szabo. 2007. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 133:1627-1636.
40. Dorrucci, M., P. Pezzotti, A. N. Phillips, A. C. Lepri, and G. Rezza. 1995. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. J. Infect. Dis. 172:1503-1508.
41. Dutoit, V., D. Ciuffreda, D. Comte, J. J. Gonvers, and G. Pantaleo. 2005. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur. J. Immunol. 35:3493-3504.
42. Eyster, M. E., M. W. Fried, A. M. Di Bisceglie, and J. J. Goedert. 1994. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 84:1020-1023.
43. Fauci, A. S., D. Mavilio, and S. Kottilil. 2005. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5:835-843.
44. Ferri, C., A. Antonelli, M. T. Mascia, M. Sebastiani, P. Fallahi, D. Ferrari, S. A. Pileri, and A. L. Zignego. 2007. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig. Liver Dis. 39(Suppl. 1):S13-S21.
45. Fierer, D. S., A. J. Uriel, D. C. Carriero, A. Klepper, D. T. Dieterich, M. P. Mullen, S. N. Thung, M. I. Fiel, and A. D. Branch. 2008. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J. Infect. Dis. 198:683-686.
46. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
47. Grakoui, A., N. H. Shoukry, D. J. Woollard, J. H. Han, H. L. Hanson, J. Ghrayeb, K. K. Murthy, C. M. Rice, and C. M. Walker. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659-662.
48. Greub, G., B. Ledergerber, M. Battegay, P. Grob, L. Perrin, H. Furrer, P. Burgisser, P. Erb, K. Boggian, J. C. Piffaretti, B. Hirschel, P. Janin, P. Francioli, M. Flepp, and A. Telenti. 2000. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356:1800-1805.
49. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77:11708-11717.
50. + T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 55:1484-1487.
51. Hoofnagle, J. H., and L. B. Seeff. 2006. Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 355:2444-2451.
52. Hornberger, J., F. J. Torriani, D. T. Dieterich, N. Brau, M. S. Sulkowski, M. R. Torres, J. Green, and K. Patel. 2006. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J. Clin. Virol. 36:283-291.
53. Housset, C., E. Lamas, V. Courgnaud, O. Boucher, P. M. Girard, C. Marche, and C. Brechot. 1993. Presence of HIV-1 in human parenchymal and non-parenchymal liver cells in vivo. J. Hepatol. 19:252-258.
54. Hufert, F. T., J. Schmitz, M. Schreiber, H. Schmitz, P. Racz, and D. D. von Laer. 1993. Human Kupffer cells infected with HIV-1 in vivo. J. Acquir. Immune Defic. Syndr. 6:772-777.
55. Kaiser, T., and H. L. Tillmann. 2005. GB virus C infection: is there a clinical relevance for patients infected with the human immunodeficiency virus? AIDS Rev. 7:3-12.
56. Kim, A. Y., J. Schulze zur Wiesch, T. Kuntzen, J. Timm, D. E. Kaufmann, J. E. Duncan, A. M. Jones, A. G. Wurcel, B. T. Davis, R. T. Gandhi, G. K. Robbins, T. M. Allen, R. T. Chung, G. M. Lauer, and B. D. Walker. 2006. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 3:e492.
57. Klein, M. B., N. Campeol, R. G. Lalonde, B. Brenner, and M. A. Wainberg. 2003. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS 17:1001-1008.
58. Labarga, P., V. Soriano, M. E. Vispo, J. Pinilla, L. Martin-Carbonero, C. Castellares, R. Casado, I. Maida, P. Garcia-Gasco, and P. Barreiro. 2007. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J. Infect. Dis. 196:670-676.
59. Lafeuillade, A., G. Hittinger, and S. Chadapaud. 2001. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280-281.
60. Laguno, M., J. Murillas, J. L. Blanco, E. Martinez, R. Miquel, J. M. Sanchez-Tapias, X. Bargallo, A. Garcia-Criado, E. de Lazzari, M. Larrousse, A. Leon, M. Lonca, A. Milinkovic, J. M. Gatell, and J. Mallolas. 2004. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18:F27-F36.
61. Larsen, C., G. Pialoux, D. Salmon, D. Antona, Y. Le Strat, L. Piroth, S. Pol, E. Rosenthal, D. Neau, C. Semaille, and E. Delarocque Astagneau. 29 May 2008, posting date. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro. Surveill. 13:pii=18888. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId= 18888.
62. Lefkowitch, J. H. 1997. The liver in AIDS. Semin. Liver Dis. 17:335-344.
63. Lin, W., E. M. Weinberg, A. W. Tai, L. F. Peng, M. A. Brockman, K. A. Kim, S. S. Kim, C. B. Borges, R. X. Shao, and R. T. Chung. 2008. HIV increases HCV replication in a TGF-β1-dependent manner. Gastroenterology 134:803-811.
64. Lissen, E., N. Clumeck, R. Sola, M. Mendes-Correa, J. Montaner, M. Nelson, J. DePamphilis, M. Pessoa, P. Buggisch, J. Main, and D. Dieterich. 2006. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 20:2175-2181.
65. López-Labrador, F. X., L. Dove, C. K. Hui, Y. Phung, M. Kim, M. Berenguer, and T. L. Wright. 2007. Trends for genetic variation of hepatitis C virus quasispecies in human immunodeficiency virus-1 coinfected patients. Virus Res. 130:285-291.
66. Ma, G., M. Moreno, W. Cardona Maya, P. Presicce, K. E. Sherman, C. Chougnet, and J. T. Blackard. 2009. HIV infection of an HCV-producing hepatocyte cell line - a model system for exploring HIV-HCV coinfection in vitro, abstr. OP-171, p. 34. 13th Int. Symp. Viral Hepat. Liver Dis., Washington, DC.
67. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
68. Marincovich, B., J. Castilla, J. del Romero, S. Garcia, V. Hernando, M. Raposo, and C. Rodriguez. 2003. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex. Transm. Infect. 79:160-162.
69. Mariné-Barjoan, E., A. Berrebi, V. Giordanengo, S. F. Favre, H. Haas, M. Moreigne, J. Izopet, J. Tricoire, A. Tran, C. Pradier, and A. Bongain. 2007. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS 21:1811-1815.
70. Martinez-Sierra, C., A. Arizcorreta, F. Diaz, R. Roldan, L. Martin-Herrera, E. Perez-Guzman, and J. A. Giron-Gonzalez. 2003. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin. Infect. Dis. 36:491-498.
71. Mauss, S., W. Valenti, J. DePamphilis, F. Duff, L. Cupelli, S. Passe, J. Solsky, F. J. Torriani, D. Dieterich, and D. Larrey. 2004. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 18:F21-F25.
72. Miller, M. F., C. Haley, M. J. Koziel, and C. F. Rowley. 2005. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin. Infect. Dis. 41:713-720.
73. Mira, J. A., L. F. Lopez-Cortes, P. Barreiro, C. Tural, M. Torres-Tortosa, I. de Los Santos Gil, P. Martin-Rico, M. J. Rios-Villegas, J. J. Hernandez-Burruezo, D. Merino, M. A. Lopez-Ruz, A. Rivero, L. Munoz, M. Gonzalez-Serrano, A. Collado, J. Macias, P. Viciana, V. Soriano, and J. A. Pineda. 2008. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J. Antimicrob. Chemother. 62:1365-1373.
74. Mira, J. A., L. F. Lopez-Cortes, D. Merino, A. Arizcorreta-Yarza, A. Rivero, A. Collado, M. J. Rios-Villegas, M. Gonzalez-Serrano, M. Torres-Tortoso, J. Macias, B. Valera-Bestard, E. Fernandez-Fuertes, J. A. Giron-Gonzalez, F. Lozano, and J. A. Pineda. 2007. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir. Ther. 12:1225-1235.
75. Miyazaki, M., T. Kanto, M. Inoue, I. Itose, H. Miyatake, M. Sakakibara, T. Yakushijin, N. Kakita, N. Hiramatsu, T. Takehara, A. Kasahara, and N. Hayashi. 2008. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I. J. Med. Virol. 80:980-988.
76. Mohsen, A. H., S. Murad, and P. J. Easterbrook. 2005. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med. 6:206-215.
77. Monforte Ade, A., R. Bugarini, P. Pezzotti, A. De Luca, A. Antinori, C. Mussini, G. M. Vigevani, U. Tirelli, R. Bruno, F. Gritti, M. Piazza, S. Chigiotti, A. Chirianni, C. De Stefano, E. Pizzigallo, O. Perrella, and M. Moroni. 2001. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J. Acquir. Immune Defic. Syndr. 28:114-123.
78. + T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy. Antivir. Ther. 11:125-129.
79. Moreno, A., C. Quereda, L. Moreno, M. J. Perez-Elias, A. Muriel, J. L. Casado, A. Antela, F. Dronda, E. Navas, R. Barcena, and S. Moreno. 2004. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir. Ther. 9:133-138.
80. Morsica, G., S. Bagaglio, S. Ghezzi, C. Lodrini, E. Vicenzi, E. Santagostino, A. Gringeri, M. Cusini, G. Carminati, G. Bianchi, L. Galli, A. Lazzarin, and G. Poli. 2007. Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression. J. Clin. Virol. 39:82-86.
81. Munshi, N., A. Balasubramanian, M. Koziel, R. K. Ganju, and J. E. Groopman. 2003. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J. Infect. Dis. 188:1192-1204.
82. Nattermann, J., H. D. Nischalke, B. Kupfer, J. Rockstroh, L. Hess, T. Sauerbruch, and U. Spengler. 2003. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 17:1457-1462.
83. Netski, D. M., Q. Mao, S. C. Ray, and R. S. Klein. 2008. Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression. J. Acquir. Immune Defic. Syndr. 49:136-141.
84. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282:103-107.
85. Nowicki, M. J., T. Laskus, G. Nikolopoulou, M. Radkowski, J. Wilkinson, W. B. Du, J. Rakela, and A. Kovacs. 2005. Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women. J. Infect. Dis. 192:1557-1565.
86. Nunez, M. 2006. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J. Hepatol. 44:S132-S139.
87. Núñez, M., A. Ocampo, K. Aguirrebengoa, M. Cervantes, A. Pascual, S. Echeverria, V. Asensi, P. Barreiro, J. Garcia-Samaniego, and V. Soriano. 2008. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J. Viral Hepat. 15:363-369.
88. Núñez, M., P. Rios, L. Martin-Carbonero, M. Perez-Olmeda, J. Gonzalez-Lahoz, and V. Soriano. 2002. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 30:65-68.
89. Payan, C., A. Pivert, P. Morand, S. Fafi-Kremer, F. Carrat, S. Pol, P. Cacoub, C. Perronne, and F. Lunel. 2007. Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG-IFN α2b plus ribavirin in HIV/HCV co-infected patients. Gut 56:1111-1116.
90. Perz, J. F., L. A. Farrington, C. Pecoraro, Y. J. Hutin, and G. L. Armstrong. 2004. Estimated global prevalence of hepatitis C virus infection, abstr. 957, p. 213. Annu. Meet. Infect. Dis. Soc. Am., Boston, MA.
91. Pham, T. N., and T. I. Michalak. 2008. Occult persistence and lymphotropism of hepatitis C virus infection. World J. Gastroenterol. 14:2789-2793.
92. Piguet, V., and R. M. Steinman. 2007. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 28:503-510.
93. Pineda, J. A., J. A. Garcia-Garcia, M. Aguilar-Guisado, M. J. Rios-Villegas, J. Ruiz-Morales, A. Rivero, J. del Valle, R. Luque, J. Rodriguez-Bano, M. Gonzalez-Serrano, A. Camacho, J. Macias, I. Grilo, and J. M. Gomez-Mateos. 2007. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46:622-630.
94. Pol, S., B. Lamorthe, N. T. Thi, V. Thiers, F. Carnot, H. Zylberberg, P. Berthelot, C. Brechot, and B. Nalpas. 1998. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J. Hepatol. 28:945-950.
95. Polis, C. B., S. N. Shah, K. E. Johnson, and A. Gupta. 2007. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin. Infect. Dis. 44:1123-1131.
96. Puoti, M., C. Torti, D. Ripamonti, F. Castelli, S. Zaltron, B. Zanini, A. Spinetti, V. Putzolu, S. Casari, L. Tomasoni, E. Quiros-Roldan, M. Favret, L. Berchich, P. Grigolato, F. Callea, and G. Carosi. 2003. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J. Acquir. Immune Defic. Syndr. 32:259-267.
97. Qurishi, N., C. Kreuzberg, G. Luchters, W. Effenberger, B. Kupfer, T. Sauerbruch, J. K. Rockstroh, and U. Spengler. 2003. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362:1708-1713.
98. Rehermann, B. 2007. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin. Liver Dis. 27:152-160.
99. Rosa, D., G. Saletti, E. De Gregorio, F. Zorat, C. Comar, U. D'Oro, S. Nuti, M. Houghton, V. Barnaba, G. Pozzato, and S. Abrignani. 2005. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc. Natl. Acad. Sci. USA 102:18544-18549.
100. Rosen, H. R., C. R. Shackleton, L. Higa, I. M. Gralnek, D. A. Farmer, S. V. McDiarmid, C. Holt, K. J. Lewin, R. W. Busuttil, and P. Martin. 1997. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am. J. Gastroenterol. 92:1453-1457.
101. Rosenthal, E., G. Pialoux, N. Bernard, C. Pradier, D. Rey, M. Bentata, C. Michelet, S. Pol, C. Perronne, and P. Cacoub. 2007. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 study). J. Viral Hepat. 14:183-188.
102. Rosenthal, E., M. Poiree, C. Pradier, C. Perronne, D. Salmon-Ceron, L. Geffray, R. P. Myers, P. Morlat, G. Pialoux, S. Pol, and P. Cacoub. 2003. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17:1803-1809.
103. Rosenthal, E., D. Salmon-Ceron, C. Lewden, V. Bouteloup, G. Pialoux, F. Bonnet, M. Karmochkine, T. May, M. Francois, C. Burty, E. Jougla, D. Costagliola, P. Morlat, G. Chene, and P. Cacoub. 2009. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med. 10:282-289.
104. Salmon-Ceron, D., C. Lewden, P. Morlat, S. Bevilacqua, E. Jougla, F. Bonnet, L. Heripret, D. Costagliola, T. May, and G. Chene. 2005. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol. 42:799-805.
105. Salmon-Ceron, D., E. Rosenthal, C. Lewden, V. Bouteloup, T. May, C. Burty, F. Bonnet, D. Costagliola, E. Jougla, C. Semaille, P. Morlat, P. Cacoub, and G. Chene. 2009. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. J. Hepatol. 50:736-745.
106. Shea, D. O., H. Tuite, G. Farrell, M. Codd, F. Mulcahy, S. Norris, and C. Bergin. 2008. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV/HIV co-infected individuals. J. Viral Hepat. 15:482-489.
107. Sherman, K. E., C. Andreatta, J. O'Brien, A. Gutierrez, and R. Harris. 1996. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 23:688-694.
108. Sherman, K. E., J. O'Brien, A. G. Gutierrez, S. Harrison, M. Urdea, P. Neuwald, and J. Wilber. 1993. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J. Clin. Microbiol. 31:2679-2682.
109. Sherman, K. E., N. J. Shire, S. D. Rouster, M. G. Peters, M. James Koziel, R. T. Chung, and P. S. Horn. 2005. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 128:313-327.
110. Shores, N. J., I. Maida, V. Soriano, and M. Nunez. 2008. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J. Hepatol. 49:323-328.
111. Shuhart, M. C., D. G. Sullivan, K. Bekele, R. D. Harrington, M. M. Kitahata, T. L. Mathisen, L. V. Thomassen, S. S. Emerson, and D. R. Gretch. 2006. HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability. J. Infect. Dis. 193:1211-1218.
112. Solmone, M., E. Girardi, E. Lalle, I. Abbate, A. D'Arminio Monforte, A. Cozzi-Lepri, A. Alessandrini, R. Piscopo, F. Ebo, L. Cosco, G. Antonucci, G. Ippolito, and M. R. Capobianchi. 2006. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy. Antivir. Ther. 11:87-94.
113. Solomon, S. S., A. K. Srikrishnan, S. H. Mehta, C. K. Vasudevan, K. G. Murugavel, E. Thamburaj, S. Anand, M. S. Kumar, C. Latkin, S. Solomon, and D. D. Celentano. 2008. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J. Acquir. Immune Defic. Syndr. 49:327-332.
114. Soriano, V., I. Maida, M. Nunez, J. Garcia-Samaniego, P. Barreiro, L. Martin-Carbonero, and J. Gonzalez-Lahoz. 2004. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir. Ther. 9:987-992.
115. Soriano, V., C. Miralles, M. A. Berdun, E. Losada, K. Aguirrebengoa, A. Ocampo, P. Arazo, M. Cervantes, I. de los Santos, I. San Joaquin, S. Echeverria, M. J. Galindo, V. Asensi, P. Barreiro, J. Sola, J. J. Hernandez-Burruezo, J. Guardiola, F. Blanco, L. Martin-Carbonero, J. Garcia-Samaniego, and M. Nunez. 2007. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir. Ther. 12:469-476.
116. Steffan, A. M., M. E. Lafon, J. L. Gendrault, C. Schweitzer, C. Royer, D. Jaeck, J. P. Arnaud, M. P. Schmitt, A. M. Aubertin, and A. Kirn. 1992. Primary cultures of endothelial cells from the human liver sinusoid are permissive for human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 89:1582-1586.
117. Stone, S. F., S. Lee, N. M. Keane, P. Price, and M. A. French. 2002. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J. Infect. Dis. 186:1498-1502.
118. Sulkowski, M. S., R. D. Moore, S. H. Mehta, R. E. Chaisson, and D. L. Thomas. 2002. Hepatitis C and progression of HIV disease. JAMA 288:199-206.
119. Sullivan, P. S., D. L. Hanson, E. H. Teshale, L. L. Wotring, and J. T. Brooks. 2006. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 20:1171-1179.
120. Tanaka, Y., K. Hanada, H. Hanabusa, F. Kurbanov, T. Gojobori, and M. Mizokami. 2007. Increasing genetic diversity of hepatitis C virus in haemophiliacs with human immunodeficiency virus coinfection. J. Gen. Virol. 88:2513-2519.
121. Tedaldi, E. M., K. H. Hullsiek, C. D. Malvestutto, R. C. Arduino, E. J. Fisher, P. J. Gaglio, E. R. Jenny-Avital, J. P. McGowan, and G. Perez. 2003. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin. Infect. Dis. 36:1313-1317.
122. Thein, H. H., Q. Yi, G. J. Dore, and M. D. Krahn. 2008. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 22:1979-1991.
123. Thomas, D. L., J. Astemborski, R. M. Rai, F. A. Anania, M. Schaeffer, N. Galai, K. Nolt, K. E. Nelson, S. A. Strathdee, L. Johnson, O. Laeyendecker, J. Boitnott, L. E. Wilson, and D. Vlahov. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450-456.
124. Thomas, D. L., J. Astemborski, D. Vlahov, S. A. Strathdee, S. C. Ray, K. E. Nelson, N. Galai, K. R. Nolt, O. Laeyendecker, and J. A. Todd. 2000. Determinants of the quantity of hepatitis C virus RNA. J. Infect. Dis. 181:844-851.
125. Torriani, F. J., M. Rodriguez-Torres, J. K. Rockstroh, E. Lissen, J. Gonzalez-Garcia, A. Lazzarin, G. Carosi, J. Sasadeusz, C. Katlama, J. Montaner, H. Sette, Jr., S. Passe, J. De Pamphilis, F. Duff, U. M. Schrenk, and D. T. Dieterich. 2004. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351:438-450.
126. Torti, C., G. Lapadula, M. Puoti, S. Casari, M. C. Uccelli, G. Cristini, D. Bella, G. Pastore, N. Ladisa, L. Minoli, G. Sotgiu, S. L. Caputo, S. Bonora, and G. Carosi. 2006. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER cohort. J. Acquir. Immune Defic. Syndr. 41:180-185.
127. Tseng, C. T., and G. R. Klimpel. 2002. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195:43-49.
128. Tuyama, A., F. Hong, A. Mosoian, P. Chen, B. Chen, A. Shecter, M. Klotman, and M. Bansal. 2007. HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV/HCV coinfection. Hepatology 46:80A.
129. UNAIDS. 2008. Report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland.
130. Vispo, E., P. Barreiro, J. A. Pineda, J. A. Mira, I. Maida, L. Martin-Carbonero, S. Rodriguez-Novoa, I. Santos, L. F. Lopez-Cortes, D. Merino, A. Rivero, and V. Soriano. 2008. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir. Ther. 13:429-437.
131. Vlahakis, S. R., A. Villasis-Keever, T. S. Gomez, G. D. Bren, and C. V. Paya. 2003. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J. Infect. Dis. 188:1455-1460.
132. Vogt, M. W., K. L. Hartshorn, P. A. Furman, T. C. Chou, J. A. Fyfe, L. A. Coleman, C. Crumpacker, R. T. Schooley, and M. S. Hirsch. 1987. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235:1376-1379.
133. Wang, X. P., L. Goodwin, P. Kahn, C. Gawel, C. B. Cunha, B. Laser, B. Sahn, and M. H. Kaplan. 2006. Influence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus I. J. Biomol. Tech. 17:228-239.
134. Weber, R., C. A. Sabin, N. Friis-Moller, P. Reiss, W. M. El-Sadr, O. Kirk, F. Dabis, M. G. Law, C. Pradier, S. De Wit, B. Akerlund, G. Calvo, A. Monforte, M. Rickenbach, B. Ledergerber, A. N. Phillips, and J. D. Lundgren. 2006. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166:1632-1641.
135. Xiang, J., S. L. George, S. Wunschmann, Q. Chang, D. Klinzman, and J. T. Stapleton. 2004. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, MIP-1β, and SDF-1. Lancet 363:2040-2046.
136. Xiao, P., O. Usami, Y. Suzuki, H. Ling, N. Shimizu, H. Hoshino, M. Zhuang, Y. Ashino, H. Gu, and T. Hattori. 2008. Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4. AIDS 22:1749-1757.